Navidea Biopharmaceuticals Received Written Notification That NYSE Is Determined To Commence Proceedings To Delist The Company's Stock; The Company's Board Will Appeal The Determination To Commence Delisting Proceedings
Portfolio Pulse from Benzinga Newsdesk
Navidea Biopharmaceuticals has received a written notification from the NYSE that it intends to commence proceedings to delist the company's stock. The company's board plans to appeal this decision.
July 31, 2023 | 8:07 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Navidea Biopharmaceuticals' stock is at risk of being delisted from the NYSE. The company's board is planning to appeal the decision.
The news of a potential delisting from the NYSE is a significant negative event for Navidea Biopharmaceuticals. Delisting often leads to a decrease in a company's stock price as it can result in less liquidity and higher trading costs. The company's board plans to appeal the decision, but the outcome is uncertain.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100